Get all your news in one place.
100's of premium titles.
One app.
Start reading
International Business Times
International Business Times
Business

BIZARRE: Eli lilly changed depression care with prozac now its betting on psychedelics with ataibeckley acquisition | Mind Blowing Facts

The acquisition gives Lilly access to AtaiBeckley's most advanced experimental treatment, BPL-003, a nasal spray that is currently being evaluated in Phase 3 clinical trials for treatment-resistant depression. (Credit: Scott Olson/Getty Images)

Eli Lilly is making its biggest move yet into the rapidly evolving field of psychedelic medicine, acquiring clinical-stage biotechnology company AtaiBeckley in a deal valued at up to $3.8 billion.

In the statement announcing the acquisition, the Indianapolis-based drugmaker said it will pay $6.75 per share in cash, valuing the transaction at approximately $2.8 billion upfront. Lilly could also pay up to an additional $2.50 per share, or roughly $1 billion, if AtaiBeckley's experimental therapies achieve specified development and regulatory milestones.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.